Wedbush Maintains Outperform on Beam Therapeutics, Raises Price Target to $33
Benzinga Newsdesk 2 hours ago
Analyst RatingsNewsPrice Target
Wedbush analyst David Nierengarten maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and raises the price target from $30 to $33.
Wedbush analyst David Nierengarten maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and raises the price target from $30 to $33.